Amipizone

Immunogen Synthetic peptide directed towards the N terminal region of human UBA3 Biochem/physiol Actions UBA3 is a catalytic subunit of the dimeric UBA3-NAE1 E1 enzyme. E1 activates NEDD8 by first adenylating its C-terminal glycine residue with

Anti-UIMC1 ubiquitin interaction motif containing 1, 100ul U

Anti-UIMC1 ubiquitin interaction motif containing 1, 100ul U

Zinc transporter ZIP6, also known as Estrogen-regulated protein LIV-1 or Solute carrier family 39 member 6 orZrt- and Irt-like protein 6 (ZIP-6), and encoded by the gene name ZIP6 or SLC39A6 or LIV1 is a member of a family of divalent ion

Biochem/physiol Actions ASB14780 can be a potential therapeutic for the treatment of asthma and other pulmonary diseases. In addition, its inhibitory function on group IVA phospholipase A2 (IVA-PLA2) qualifies this drug to be a potential

Biochem/physiol Actions ASB14780 can be a potential therapeutic for the treatment of asthma and other pulmonary diseases. In addition, its inhibitory function on group IVA phospholipase A2 (IVA-PLA2) qualifies this drug to be a potential

AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 mitigates the GABA binding and hepatic toxicity signal. AZD9898 has the potential to treat asthma.

AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 mitigates the GABA binding and hepatic toxicity signal. AZD9898 has the potential to treat asthma.

Application 500 kDa NMWL, Biomax polyethersulfone, 44.5 mm diameter Legal Information Amicon is a registered trademark of Merck KGaA, Darmstadt, Germany BIOMAX is a registered trademark of Merck KGaA, Darmstadt, Germany

Cell Line Origin Human Caucasian lung Cell Line Description Derived from a lung explant of a 1 month old Caucasian male with congenital heart disease. Application Ageing studies Culture Medium EMEM (EBSS) + 2mM Glutamine + 1% Non Essential Amino

CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC 50 &gt: 1 μMIn VitroCDK12-IN-E9

CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC 50 &gt: 1 μMIn VitroCDK12-IN-E9